Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Jun 8, 2026 · Filed Jun 9, 2026
The boss of ResMed| sold $968K of ResMed| shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$968,064
Shares × reported transaction price
39 days after results of Apr 30, 2026, 29 days before results of Jul 7, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $193.14 on Jun 8, 2026, 6% above its 52-week low and 34% below its high, after a 12% drop over the previous 30 trading days
52-week range $182.82 (Jun 2, 2026) to $293.73 (Aug 22, 2025), 9% of the way up, from 251 adjusted closes. 30 trading days earlier: $219.85 on Apr 24, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -3.8% | +2.1% | -5.9% |
| 30 days | +5.3% | +4.1% | +1.3% |
| 90 days | +14.2% | +5.6% | +8.6% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.